Hongshan

Hongshan, formerly Sequoia Capital China, is the powerhouse Chinese venture and growth firm that spun out from the broader Sequoia franchise to operate independently in Greater China. Headquartered in Beijing with operations across Chinese commercial centers, Hongshan manages substantial assets and has produced many of the most consequential Chinese technology and healthcare companies of the past two decades.

The healthcare thesis covers biotech, pharma and therapeutics, and AI and machine learning applied to healthcare. Notable portfolio activity includes ArriVent BioPharma, a clinical-stage biopharmaceutical company that illustrates Hongshan’s appetite for serious therapeutic platforms alongside its better-known consumer technology investments. The firm’s healthcare strategy spans early science platforms through growth-stage clinical assets, with pattern recognition built across hundreds of life sciences and healthcare investments.

Hongshan writes $25M-plus checks and is active from Seed through Growth, which is the full lifecycle stage coverage that defines a multi-stage firm. Geographic focus is Greater China, with portfolio companies routinely expanding into US and global markets, and the firm’s capital depth means it can lead or co-lead at any stage where conviction warrants it. Founders raising sub-$25M rounds should expect the firm to participate selectively rather than as a default lead.

The team is among the largest and most experienced in Chinese venture capital, with specialist healthcare partners alongside the broader technology and growth franchises. Specific partner names are not provided in the source data, and founders should engage through Hongshan’s main channels and expect routing to the partner whose expertise aligns with the underlying sector and stage.

The approach is high-conviction and lifecycle-spanning. Hongshan invests with the expectation of building category-defining companies and is willing to underwrite serious commercial and clinical risk to support that ambition. The firm is a strong fit for Chinese healthcare and AI founders building category leaders who benefit from a long-term institutional partner with substantial follow-on capacity. Founders without category-leadership ambitions or those operating outside the Chinese context will find less structural alignment.